Claims
- 1. A human interleukin-2 composition in the form of an aqueous solution or frozen matter which comprises in addition to human interleukin-2, human serum albumin in a concentration of about 0.1 to 50 mg/ml as an aqueous solution, and, as a solution, is adjusted to have a pH between 3 to 5.5.
- 2. The composition according to claim 1, wherein the human interleukin-2 is a recombinant human interleukin-2.
- 3. The composition according to claim 1, wherein the human interleukin-2 is a non-glycosylated human interleukin-2.
- 4. The composition according to claim 1, wherein the human interleukin-2 has a specific activity of 20,000 to 80,000 units/mg.
- 5. The composition according to claim 1, wherein the human interleukin-2 is in a concentration of 1 to 80,000 units/ml as an aqueous solution.
- 6. The composition according to claim 1, which is free from a salt.
- 7. The composition according to claim 1, which further comprises a monoamino aliphatic amino acid, a cyclic amino acid, a monosaccharide, a sugar alcohol or a combination thereof.
- 8. The composition according to claim 1, which further comprises a monoamino aliphatic amino acid.
- 9. The composition according to claim 8, wherein the monoamino aliphatic amino acid is in a concentration of 5 to 50 mg/ml as an aqueous solution.
- 10. The composition according to claim 1, wherein the pH of the composition is adjusted by an acidic reducing compound, an acidic amino acid, a mineral acid or/and a buffer of organic acid.
- 11. The composition according to claim 7, wherein the additional component is a monosaccharide, a sugar alcohol or a combination thereof in a concentration of 10 to 100 mg/ml.
- 12. The composition according to claim 1, comprising a combination of the human serum albumin and a reducing compound.
- 13. The composition according to claim 12, wherein the reducing compound is an acidic reducing compound.
- 14. The composition according to claim 13, wherein the acidic reducing compound is glutathione, thioctic acid, N-acetylcysteine, thioalkanoic acid of 1 to 7 carbon atoms or ascorbic acid.
- 15. The composition according to claim 12, wherein the reducing compound is in a concentration of 0.05-20 mg/ml as an aqueous solution.
Priority Claims (3)
Number |
Date |
Country |
Kind |
59-71568 |
Apr 1984 |
JPX |
|
60-13226 |
Jan 1985 |
JPX |
|
60-37184 |
Feb 1985 |
JPX |
|
Parent Case Info
This is a division of co-pending application Ser. No. 720,754, filed on Apr. 8, 1985, now U.S. Pat. No. 4,645,830.
US Referenced Citations (7)
Foreign Referenced Citations (3)
Number |
Date |
Country |
0091258 |
Aug 1983 |
EPX |
0145390 |
Jun 1985 |
EPX |
2532178 |
Aug 1983 |
FRX |
Non-Patent Literature Citations (3)
Entry |
Mier, James W., et al., Journal of Immun., vol. 128, (3), 3/82. |
Rubin et al. PNAS, 77, No. 10, 5928-5932 (1980). |
Taniguchi et al., Nature, 302, 305-310 (1983). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
720754 |
Apr 1985 |
|